Tropocells

What Tropocells does

Tropocells is a brand of Estar Technologies Ltd., an Israeli private medical device company headquartered in Holon, Israel, that develops and markets autologous regenerative-medicine products built on a patented gel-barrier separation technology. The company's flagship product, Tropocells® PRP, is an FDA 510(k) Class II cleared device that uses a single-spin centrifugation process with a proprietary separator gel to isolate platelets from whole blood, achieving roughly 80% platelet yield while removing 100% of red blood cells and 92–96% of neutrophils and preserving monocytes and lymphocytes. Around this core PRP platform, the company offers a family of consumable-based adjunct products — TropoVisc™ (autologous visco supplementation), Tropokine™ (autologous IL-1Ra conditioned serum), Tropocells® PRF (fibrin scaffold), Tropocells® TRS (autologous thrombin-rich serum), and Tropocells® PRFM (fibrin matrix) — that address procedures in orthopedics and sports medicine, wound management, dental and maxillofacial surgery, and ophthalmology.

The business model is a classic medical-device razor-and-blade: the company sells an affordable, moderately priced centrifuge and a portfolio of single-use consumable kits (tubes, vials, and reagents) to healthcare practitioners. Tropocells runs a channel-led go-to-market, distributing through a global network of regional representatives and distributors, supported by a dedicated Distributor Portal (myportal.tropocells.com), separate U.S. and international websites, and a clinical-education-heavy marketing apparatus built around peer-reviewed publications, product brochures, demo videos, and named-physician testimonials. Pricing is quote-based and not publicly disclosed. The company is privately held by Estar Medical, which has been developing medical technology for over 30 years since 1992, and operates with a headcount in the 11–50 range; no external funding rounds, acquisitions, or public-market events are disclosed in the available data.

Name

Tropocells

Legal name

Estar Technologies Ltd.

Website

https://tropocells.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Short description

Tropocells, a brand of Israel's Estar Technologies Ltd., develops FDA-cleared autologous platelet-rich plasma (PRP) systems and related regenerative-medicine consumables using a patented gel-separation technology. It sells through global distributors to orthopedic, sports medicine, dental, wound care, and ophthalmology practitioners.

Ownership category

akta.pro rank

Headquarters

HQ city

Watford

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Device Sales (PRP Systems and Consumables): Tropocells generates revenue through the sale of its FDA-cleared medical devices and consumables including Tropocells® PRP tubes, TropoVisc™, Tropokine™, Tropocells® PRF, TRS, and PRFM products. These are sold to healthcare providers (orthopedic clinics, sports medicine practices, dental offices, wound care centers, ophthalmology practices) through distributor networks. The centrifuge equipment is described as affordable and moderately priced, with the primary consumable revenue coming from the collection tubes and related products.
2. Direct Medical Device Sales: Sale of Tropocells® PRP system components including collection tubes, centrifuge equipment, and accessories to medical practitioners. The website references both the centrifuge (affordable and moderately priced) and the tube-based system as revenue streams. Professional services revenue may be generated through distributor support and training materials.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Tropocells develops, manufactures, and markets FDA-cleared medical device systems and consumables for autologous regenerative medicine, centered on its patented gel-barrier platelet-rich plasma (PRP) separation technology. Its product portfolio includes Tropocells PRP, TropoVisc, Tropokine, Tropocells PRF, TRS, and PRFM, sold to orthopedic, sports medicine, wound care, dental, and ophthalmology clinics and practitioners globally through a distributor network.

Product overview

Tropocells offers a comprehensive portfolio of autologous regenerative medicine products centered on its patented gel separation technology for PRP preparation. The core product, Tropocells® PRP, is an FDA-cleared 510(k) medical device that uses a single-spin process to produce high-purity platelet concentrate. The platform extends through complementary products: TropoVisc™ provides visco supplementation as a PRP carrier for sustained release; Tropokine™ delivers IL-1Ra-based anti-inflammatory therapy; Tropocells® TRS enables platelet activation; and Tropocells® PRF/PRFM create fibrin scaffolds for different healing applications. These products serve orthopedics, sports medicine, wound management, dental, and ophthalmology treatments.

Differentiator

Problem solved

Functional benefit

Brands

• Tropocells PRP: Platelet-Rich Plasma preparation system for autologous regenerative medicine, utilizing patented gel separation technology.
• TropoVisc
• Tropokine
• Tropocells PRF
• Tropocells TRS
• Tropocells PRFM

Products and services

• Tropocells PRP FDA 510(k) cleared Class II medical device system for the rapid point-of-care preparation of autologous platelet-rich plasma (PRP) from a small blood sample, using a patented gel-barrier separation technology that yields approximately 80% platelet recovery, removes 99.9% of red blood cells and 92–96% of neutrophils, and preserves monocytes and lymphocytes for tissue regeneration across orthopedic, sports medicine, wound care, dental, and ophthalmology applications.
• TropoVisc Autologous visco supplementation product that uses denaturized plasmatic proteins (albumin-rich PPP) to form a mesh-like scaffold acting as a biological cell carrier for sustained growth factor release, maintaining PRP efficacy at the injection site for up to two months.
• Tropokine Next-generation autologous conditioned serum therapy built on the Tropocells PRF platform that concentrates IL-1Ra (Interleukin-1 Receptor Antagonist) through a simple single-spin preparation to control inflammation and support tissue regeneration by blocking IL-1 signaling.
• Tropocells PRF Autologous polymerized fibrin scaffold consisting of platelet cytokines, growth factors, and chemokines. Unlike common PRF methods, it requires no bovine thrombin or anticoagulants and achieves a clot with 95% platelets, less than 1% red blood cells, and 1% white blood cells for slow release of growth factors.
• Tropocells TRS Autologous Thrombin-Rich Serum technology that enables physicians to activate platelets derived from Tropocells PRP, releasing enriched growth factors that stimulate, accelerate, and enhance the body's natural healing processes at localized surgical sites.
• Tropocells PRFM Platelet Rich Fibrin Matrix (PRFM) derived by combining Tropocells PRP with autologous thrombin (TRS), providing a flexible fibrin gel matrix platform that enables control of PRP concentration and matrix diameter for targeted regenerative applications.

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

One partnership is on record.

• Estar Medical / Estar Technologies LtdcoreStrategic or Co-development PartnerTropocells is a product line of Estar Medical (Estar Technologies Ltd.), which has been developing medical technology for over 30 years since 1992. Estar Medical drives advancements through the integration of research, expert insights, and innovative therapies. Tropocells is part of a full line of products for tissue regeneration developed by Estar Medical, alongside the Cellenis® brand. The company website (tropocells.com) is operated by Estar Technologies Ltd. along with www.estar-medical.com and www.cellenis.com.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Arthrex: Arthrex manufactures the ACP (Autologous Conditioned Plasma) Double Syringe system, one of the most widely adopted PRP preparation devices in orthopedics and sports medicine. Arthrex is a direct competitor to Tropocells, serving the same orthopedic surgeon and sports medicine physician customer base with a comparable point-of-care PRP workflow.
• Regen Lab: Regen Lab is a Swiss medical device company specializing in PRP and cell therapy preparation kits (RegenKit), sold globally for orthopedic, dermatology, wound healing, and dental applications. Regen Lab is a direct competitor with a comparable tube-based separation approach and overlapping multi-vertical market positioning.
• Emcyte Corporation: Emcyte Corporation manufactures PurePRP and concentrated bone marrow aspirate systems used by orthopedic surgeons, sports medicine physicians, and wound care specialists. Emcyte directly competes with Tropocells in the autologous PRP preparation device category targeting the same clinical use cases.
• BTI Biotechnology Institute: BTI Biotechnology Institute (Spain) markets the PRGF-Endoret system, a widely adopted autologous PRP technology for dental implantology, oral surgery, and orthopedics. BTI is a direct competitor in dental and maxillofacial regenerative medicine where it has particularly strong market presence, overlapping with Tropocells' dental vertical.

Broad incumbents

• Exactech: Exactech is an orthopedic medical device company offering implants, biologic solutions, and regenerative medicine products for joint replacement and sports medicine. As a mid-size orthopedic incumbent, Exactech competes with Tropocells for the same orthopedic surgeon customer base across biologic adjuncts used in surgical and sports medicine applications.
• Terumo BCT: Terumo BCT acquired Harvest Technologies (SmartPReP PRP system) and operates broadly in blood component collection, cell therapy processing, and regenerative medicine. As a large incumbent in blood/biologic processing, Terumo BCT competes with Tropocells in the PRP device space while also serving much broader therapeutic apheresis and cell therapy markets.
• Stryker: Stryker is a large global orthopedics and medical device company with regenerative medicine offerings including PRP and bone marrow concentration systems. While Stryker's PRP products are part of a much broader portfolio, the company competes with Tropocells for the same orthopedic and sports medicine physician customers with deeper R&D resources and direct sales reach.
• Zimmer Biomet: Zimmer Biomet is a major orthopedic medical device manufacturer that sells regenerative medicine and biologic solutions (including PRP adjuncts) to orthopedic surgeons. As a broad incumbent with significantly larger scale, Zimmer Biomet competes indirectly with Tropocells across orthopedics where both address the same surgical workflow with PRP-based products.

Emerging players

• Geistlich Pharma: Geistlich Pharma is a Swiss dental regenerative medicine company primarily known for bone and soft tissue graft substitutes (Bio-Oss, Bio-Gide), with adjacent activity in PRP and biologic adjuncts for dental procedures. Geistlich competes in the same dental/maxillofacial vertical as Tropocells and represents an emerging competitor expanding into the regenerative adjunct space.
• Royal Biologics: Royal Biologics is an emerging regenerative medicine company offering autologous PRP and stem cell therapies for orthopedic and wound care applications. As a smaller specialty player with overlapping product offerings, Royal Biologics competes with Tropocells in the same point-of-care PRP kit category with comparable go-to-market through physician and clinic channels.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/estarmedical
• Facebookfacebook.com/EstarMedical
• LinkedInlinkedin.com/company/tropocells-usa

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tropocells